| Jul 23 |
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2024 Earnings Call Transcript
|
| Jul 23 |
Kiniksa Pharmaceuticals International, plc 2024 Q2 - Results - Earnings Call Presentation
|
| Jul 23 |
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates
|
| Jul 23 |
Kiniksa Pharmaceuticals GAAP EPS of -$0.06 misses by $0.01, revenue of $108.63M beats by $17.36M
|
| Jul 23 |
Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution
|
| Jul 22 |
Kiniksa Pharmaceuticals Q2 2024 Earnings Preview
|
| Jul 16 |
Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024
|
| Jul 12 |
The 13% return this week takes Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) shareholders three-year gains to 60%
|
| Jul 9 |
Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren’s Disease
|
| Jun 28 |
Kiniksa Pharmaceuticals files for $400M mixed shelf
|
